Gilead, Galapagos finalise £4.1bn research and development deal

This article was originally published here

The deal signed last month by the US-based Gilead Sciences and Galapagos has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 by the US Federal Trade

The post Gilead, Galapagos finalise £4.1bn research and development deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply